Document 0966
 DOCN  M95A0966
 TI    Fast, complete and persistent eradication of papilloma warts as
       additional activity of an anti-infective against RNA viruses (Meeting
       abstract).
 DT    9510
 AU    Wirth-Bronkowska LE; Wirth UV; aiRVi-Institute, Hohenweg 7, CH-5426
       Lengnau
 SO    Experientia; 50:A26 1994. Unique Identifier : AIDSLINE ICDB/95611721
 AB    Originally an anti-infectious drug against RNA viruses (aiRVi) was
       developed. Two different entities such as a biological and a chemical
       activity unit are necessary for efficiency of aiRVi. This antiviral drug
       could be used for disinfection, prevention and local therapy of RNA
       virus infections. Model systems will be developed, such as disinfection
       for hepatitis A, prevention against HIV causing pandemics AIDS and local
       therapy against tumor RNA viruses. During test phase of aiRVi in
       compatibility studies, a volunteer asked to get treatment of a permanent
       papilloma wart, that had not been eradicated with standard medical
       techniques up to that moment. Four days after the last operative
       excision of this wart on the finger it was obvious that the virus was
       establishing a new wart in the center of the wound again. At this time
       point, aiRVi was applied twice a day on the wound for two days. During
       this short time period the developing new wart was completely eradicated
       and never returned again now up to 3 month. The whole therapeutic
       procedure is recorded on video 8 tape, such tapes function as optimal,
       handy and cheap audiovisual lab-journals, which can be used later as
       proof and for documentation. In conclusion, beside the high potential of
       aiRVi against RNA virus infections, it seems that aiRVi is effective for
       DNA virus infections as well. Thus it would be interesting to examine,
       if other DNA virus infections (eg herpes viruses) or other localized
       tumors (eg skin tumors) could be treated as well.
 DE    Antiviral Agents/PHARMACOLOGY/*THERAPEUTIC USE  Condylomata
       Acuminata/*DRUG THERAPY/VIROLOGY  Human  Papillomavirus, Human/*DRUG
       EFFECTS  RNA Viruses/*DRUG EFFECTS  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).